Yes it's a joke, and CTIX needs to counter sue when dismissed. But many firms are restricted from buying until matters like this clear up.
CTIX is my gamble, but they have multiple shots on goal, not a one drug do or die situation. About 6 months ago no one even gave P the time of day. They seem to do a good job on pre-clinicals, and clinicals before taking next steps.
I don't know if your Bite, or another short posting here, but with the Mako smear, and Rosen Lawsuit.... the market is factoring in that the lawsuit is 80% going to win, and the drugs are going to fail. So if only 1 drug had promise recognized by Wall street, it will fly.
expecting, and senselessly selling or shorting on.. Outlook re-affirmed. Will be buying more.
They are and raised guidance. They are saying the Rev # is a miss, but its $8M on $2.5B I would call that in line. Raising revenue guidance. This just keeps getting cheaper on a NPV basis. I'll load up some more. You look of market distortions, this one smacks you in the face over and over again.
willl rule for awhile, IMHO.
I have some of PRO's concerns. The LVT's could cause a label restriction. Not sure about GONO, I think they could have released the completed PHIII and supplemented with this new one. I bought some for the trade today, but will pull the trigger if things go wrong. The earnings picture is not looking great for the S&P.
We are down more than we were in the depths of the last recession given the forward PE. Are we in a recession yet? I think Credit Suisse just called the bottom, like so many analyst's seem to do.
available biotech's, may also force others to make move too. GILD will be left in the dust. They seem paralyzed to do anything. They need to transform themselves from this one drug Co. CELG or BMRN would be good picks, but I am sure they will be scooped up soon. If they go the small ball approach, I think that will take too long to make meaningful difference. IMHO.
Look at how long this has been going on and the SEC does nothing. I think, as Mark Cuban does, they are incompetent unable to do what is needed for getting the needed reforms. The market and thieves are always 10 steps ahead. What is interesting the hedge funds cried about the uptick rule, and the SEC wasted little time in getting it removed....hmm?
I saw that, makes me think about adding to my position.
Appreciate your input Pro. Keep feeding it here. Getting tired of the relentless pumping on a stock that's been more than halved, with a CEO that thought was dishonest on the shelf, in my opinion.
Geez, CEO is doing a remarkable job so far getting others to pay for the trials to put CTIX in a position to command more $$$ from a partner. Are you one of the ones in this camp:
1) Where's K Data, trial not must be a success... Leo came through.
a. Rant 1 K must not be showing efficacy ... it did.
b. Ran 2 K must have safety issues ... it did not.
2) Where is the B Data trial must not be a success...Leo came through.
a. Rant 1 B must be showing signs of ALT liver levels or something's not good -- it did not.
b. Rant 2 B is dragging on, why, whats wrong...data can't be better than the standard--wrong.
3) When will the P trial every start, must be a loser.
a. Rant 1, P must not have a valid patent ... proven they do.
b. Rant 2, P will never start until after B and K PHIII....not results soon.
4) Pipeline can't be that valuable, none of the big boy's picked it up at Bankrupt sale.
-- Well now its looking like it was a stroke of Genius by Leo...way to go Leo!!!
-- FDA is validating the pipeline as it progresses in clinicals with more and more designations.
5) OMG did you read these articles I going to sell, or I am part of the short scam:
-- Ben S. The HS teacher.
6) CLDX management is an example of what management CTIX needs...LOL!
All these articles read as incoherent, illogical, incorrect on pretty much all their article's content. Mako being completely dismantled, now looking like a Hedge fund or illegal London outfit maybe behind the articles to make $$$ on their short positions.
I could go on and on...so many more examples.. At the same time it did allow me to double my position.
Regardless of Bernie or Hillary. The rest of the marke's growth projections down right s u c k s compared to Biotechs like CELG, BMRN, AMGN, etc.
my rear end off. I did manage to buy some shares. Almost too funny.
Might have been 2 years ago. I don't remember because I can't find the article anymore. Thanks for being a pin-head!
Time will tell what it is, although this may make similar moves small bio's in the past that move 4X before anyone knows what happened. In any case, people will be looking at this move closely over the weekend. Maybe its the P results. If anything close to the pre-clinical's there is not telling how high this can go. Someone mentioned $20, $50 very much in the realm of possibilities if P proves out. I remember an old (SA3-4 years ago) article that assessed the pipeline it really generated the revenue Dr. Menon estimated for the big 3, this could be a $200 stock. It's great to speculate; especially after all the short attacks, which are now shown to be a total fabricated lie. Can hardly wait for the dismissal and counter-suit. I bought some more on the move, hate to do it on a big move, but this could get away fast from you at these prices.